SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

TEL AVIV, Israel, Feb. 27, 2024 -- SciSparc Ltd. , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central...

Related Keywords

United States ,Israel , ,Scisparc Ltd ,Company Or Scisparc ,Exchange Commission ,Nasdaq ,Trademark Office ,Clearmind Medicine Inc ,Clearmind Medicine ,Patent Cooperation Treaty ,United States Patent ,Tourette Syndrome ,Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,